These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3776105)

  • 1. [Preparation of inactivated poliomyelitis vaccine with attenuated Sabin strains].
    Abe S; Yamaki A; Doi Y
    Uirusu; 1986 Jun; 36(1):125-37. PubMed ID: 3776105
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.
    Verdijk P; Rots NY; Bakker WA
    Expert Rev Vaccines; 2011 May; 10(5):635-44. PubMed ID: 21604984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
    Minor PD
    Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid and accurate identification of poliovirus strains used for vaccine production.
    Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
    J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.
    Shimizu H
    Vaccine; 2016 Apr; 34(16):1975-85. PubMed ID: 25448090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis.
    Swartz TA; Handsher R; Manor Y; Stoeckel P; Barkay A; Mendelson E; Leventhal A
    Vaccine; 1998 Dec; 16(20):2090-5. PubMed ID: 9796069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
    Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
    Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term use of oral poliovirus vaccine from Sabin strains in the Soviet Union.
    Grachev VP
    Rev Infect Dis; 1984; 6 Suppl 2():S321-2. PubMed ID: 6740068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved inactivated poliovirus vaccine: an update.
    Bernier RH
    Pediatr Infect Dis; 1986; 5(3):289-92. PubMed ID: 3725638
    [No Abstract]   [Full Text] [Related]  

  • 11. Sabin type 2 polioviruses with intertypic vaccine/vaccine recombinant genomes.
    Georgopoulou A; Markoulatos P
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):792-9. PubMed ID: 11783695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
    Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
    Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A seroprevalence study of poliovirus antibody against a collection of recombinant and non-recombinant poliovirus vaccine strains in the population of southern Greece.
    Pliaka V; Ruether IG; Kyriakopoulou Z; Kioussi P; Plakokefalos E; Megalou M; Pratti A; Levidiotou-Stefanou S; Markoulatos P
    Clin Microbiol Infect; 2010 Nov; 16(11):1672-5. PubMed ID: 20148919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus.
    Korotkova EA; Gmyl AP; Yakovenko ML; Ivanova OE; Eremeeva TP; Kozlovskaya LI; Shakaryan AK; Lipskaya GY; Parshina IL; Loginovskikh NV; Morozova NS; Agol VI
    J Virol; 2016 Jul; 90(13):5978-88. PubMed ID: 27099315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine--supplementary statement.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1987 Dec; 36(48):795-8. PubMed ID: 3119980
    [No Abstract]   [Full Text] [Related]  

  • 16. Leads from the MMWR. Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine--supplementary statement.
    JAMA; 1988 Jan; 259(3):345-6. PubMed ID: 3336150
    [No Abstract]   [Full Text] [Related]  

  • 17. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982.
    Dömök I
    Rev Infect Dis; 1984; 6 Suppl 2():S413-8. PubMed ID: 6740083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
    Pliaka V; Kyriakopoulou Z; Markoulatos P
    Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication.
    Knowlson S; Burlison J; Giles E; Fox H; Macadam AJ; Minor PD
    PLoS Pathog; 2015 Dec; 11(12):e1005316. PubMed ID: 26720150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicine and the media: polio still paralyses (Albert Sabin, Jonas Salk).
    Dixon B
    Br J Hosp Med; 1977 Dec; 18(6):595. PubMed ID: 342023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.